Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

Plain-language summary

Background: \- Ebola is a viral infection that can spread quickly and causes life-threatening disease. Right now there is an Ebola outbreak in many countries in West Africa. There are no approved treatments for Ebola. But possible treatments are being developed. Researchers need to study these treatments to see if they help people get better. Objective: \- To identify possible Ebola treatments. Also, to learn if adding 1 or more experimental drugs to advanced Ebola care can reduce the risk of death. Eligibility: \- People who have recently been diagnosed with Ebola, usually by a test called the Polymerase Chain Reaction (PCR), and have been hospitalized in an isolation unit for treatment. Design: * Participants will be randomly assigned to Group A or B. Both groups will get advanced level care. One group will also get an experimental drug. * Participants may have blood tests. They may have another PCR test. * Researchers will try to learn how the participant got Ebola. * Participants put in the experimental drug group may start taking medicine within 24 hours of enrollment. It may be given by mouth or intravenously. Additional doses may be needed. * Participants may have a series of timed blood tests over the first 24 to 48 hours after they take the medicine. * Blood will be drawn frequently. Other body fluids (urine, stool, vaginal fluid, etc.) may also be collected. * Participants will be followed for up to 60 days. They may be evaluated for any long-term effects of the experimental treatment(s). They may be asked to return for 1 or more outpatient visits. * For consenting participants, follow-up will be extended for up to one full year past Day 58 with contact/visits every 1-3 months to assess for a history of signs or symptoms potentially consistent with late onset of virologic relapse syndrome.

Who can participate

What they're measuring

Trial details